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Achieving the millennium development goals for health
Methods to assess the costs and health effects of
interventions for improving health in developing
countries
David B Evans, Tessa Tan-Torres Edejer, Taghreed Adam, Stephen S Lim, for the WHO Choosing
Interventions that are Cost Effective (CHOICE) Millennium Development Goals Team
Assessment of the cost effectiveness of interventions
designed to achieve the millennium development
goals for health is complex. The methods must be
capable of showing the efficiency with which current
and possible new resources are used, and incorporat-
ing interactions between concurrent interventions and
the effect of expanding coverage on unit costs.1 They
should also allow valid comparisons across a wide
range of interventions. Here we describe how the
standardised cost effectiveness methods used in the
World Health Organization’s Choosing Interventions
that are Cost Effective (CHOICE) project have tackled
these issues.
Level of analysis
The analysis was performed for 14 regions classified by
WHO according to their epidemiological grouping
(table A on bmj.com). The regional results (except if
not relevant to the disease area, for example, malaria)
are available at www.who.int/choice, but the papers in
this series give details for just two regions: Afr-E, which
includes countries in sub-Saharan Africa with high
child mortality and very high adult mortality, and
Sear-D, which comprises countries in South East Asia
with high child and adult mortality.2–6
Definition and selection of interventions
The term intervention is defined to include any
preventive, promotive, curative, or rehabilitative action
that improves health. Interventions are analysed
individually and then in combinations or packages that
could be undertaken together (box 1), taking into
account interactions in costs or effectiveness, or both.
Interventions were chosen for analysis either
because they are commonly used or because disease
control experts have advocated their introduction. In
each case, some evidence was needed that the
intervention could be effective. The list is not
exhaustive, and excluding an intervention does not
imply it is cost ineffective.
All interventions and combinations are assessed
assuming they are implemented for 10 years starting in
2000, the year the Millennium Declaration was signed.
Good policy making would then require a reassess-
ment of strategies. Costs, therefore, are only incurred
over 10 years, but all benefits accruing because of
actions taken between 2000 and 2010 are included.
Intervention costs
Costs are measured from the perspective of society as
a whole, to understand how best to use resources
regardless of who pays for them, or indeed, whether
they are paid for at all. For example, village volunteers
working for maternal health must be included because
they could be working for some other health
programme if they did not work for maternal health.
All resources used for each intervention or combina-
tion are included and valued.
Data on the costs incurred by people to access
services (such as travel costs) are rarely available, and
we, like most other studies, have excluded them.7 8 We
also excluded domestic taxes; from the perspective of
the society, they simply transfer financial resources
from one person to another and do not use up a physi-
cal resource such as capital or labour. The effect of
interventions on the time and potential earnings of
patients and unpaid carers—that is, work time lost—is a
vexing question in cost effectiveness analysis but, as
here, it is often excluded on ethical grounds. Inclusion
would give priority to extending the life of people who
earn more (box A on bmj.com).9 10
Costs are evaluated assuming 80% use of capacity
(technical efficiency) for all interventions; this is
relatively high but achievable. Use of a constant figure
ensures that differences in cost effectiveness ratios are
due to fundamental differences in the technologies or
strategies adopted and not simply to an intervention
being implemented poorly in a dysfunctional health
system. Accordingly, the results provide practical
Members of the WHO-CHOICE Millennium Development Goals
Team and further details of the methods are on bmj.com
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information about the appropriate mix of interven-
tions for various levels of resource, assuming interven-
tions are implemented relatively efficiently.
Classification and measurement of costs
Costs are divided into patient and programme levels.
Patient level costs include face to face delivery by a
health provider—for example, medicines, outpatient
visits, inpatient stays, and individual health education
messages. Programme level costs include all resources
required to establish and maintain an intervention:
administration, publicity, training, and delivery of
supplies.
We used a standardised ingredients approach to
measure costs, requiring information on the quantities
of physical inputs needed and their unit cost. Total
costs are quantities of inputs multiplied by their unit
costs. To obtain programme level costs, we commis-
sioned costing experts to collect data in 17 countries
on the physical inputs (human resources, office space,
vehicles, electricity, other services, and consumables)
required to introduce and run an intervention using a
standard template.11–13 This was supplemented by
information from programme managers in other
countries known by WHO staff.
For patient level costs, quantities were taken from
various sources. When published studies of effective-
ness were available we used these to identify the
resources necessary to ensure the observed level of
effectiveness. In other cases, we estimated the resources
required from the activities outlined in WHO
guidelines for treatment.14–17 Programme experts
checked the face validity of all estimated quantities. We
could not always determine the quantities of primary
inputs (human resources, consumables), so we esti-
mated quantities and prices at an intermediate level for
several inputs: inpatient days at different hospital
levels, outpatient visits, and health centre visits.
Unit costs for each input were derived from an
extensive search of published and unpublished
literature and databases along with consultation with
costing experts. The full costing database is available at
www.who.int/choice. For goods that are traded
internationally, we used the most competitive price
available internationally. For example, drug prices were
taken from the latest WHO negotiated prices. A
mark-up was included for transportation costs. For
goods available only locally (human resources,
inpatient bed days, etc) unit costs vary substantially
within countries. We therefore ran cross country
regressions using the collected data to estimate the
average cost (with adjustments for use of capacity) for
each setting.11–13 18
Variations in scope and scale
Some interventions can share resources like vehicles,
buildings, and administrative staff, so the costs of doing
both together are less than the sum of the costs of the
two individual programmes. We carefully identified
possible shared costs when combinations of interven-
tions were evaluated (box B on bmj.com).
Costs were estimated at three standard levels of
coverage: 50%, 80%, and 95%. We assumed that
interventions are first provided to, or obtained by, easy
to reach populations. Coverage then expands to more
outlying, sparsely populated areas. Facilities still need
to be built despite the lower population density, so use
of capacity will be lower, and the costs per patient
treated correspondingly higher at higher levels of cov-
erage. On the other hand, some interventions require a
fixed number of staff, office space, or equipment to
begin work. The same people and resources cope with
increases in coverage so the programme level costs can
be spread over a larger population, reducing the costs
per person covered. Both types of effects are included
in the costing exercise, and the net effect varies by
intervention.
Costs are reported in international ($I) rather than
US dollars with 2000 the base year (box 2). Future costs
are discounted to 2000 values using a 3% discount
rate.19 These costs do not translate directly into the
financial or cash requirements to run or expand inter-
ventions. Estimates of the cash requirements are
already available.20–24 Here, we estimate the opportunity
cost of all resources required to provide interventions,
regardless of who pays for them, to explore the combi-
nation of interventions that makes the best use of these
resources.
Assessing the effect of interventions
Interventions improve health through their effect on
incidence, remission, severity, and mortality. We
obtained efficacy data from (in order of preference)
systematic reviews with meta-analysis; randomised
studies, and before and after evaluations of country
Box 1: Analysis of individual and combined
interventions
Interventions are analysed individually and then in
combinations that could be undertaken together. This
requires a decision about whether interventions are
independent (they can be done at the same time in a
population, with or without interactions) or mutually
exclusive (if one is chosen, another cannot be).
Independent interventions can be added to existing
interventions, while mutually exclusive interventions
must replace an existing intervention.
Consider three individual antenatal interventions:
tetanus immunisation, screening for pre-eclampsia,
and screening and treatment for asymptomatic
bacteriuria. They are independent, so all possible
combinations of the interventions would be:
Tetanus immunisation + screening for pre-eclampsia
Tetanus immunisation+screening and treatment for
asymptomatic bacteriuria
Screening for pre-eclampsia+screening and
treatment for asymptomatic bacteriuria
Tetanus immunisation+screening for pre-eclampsia
and asymptomatic bacteriuria.
All the scenarios are assessed for different coverage
levels (50%, 80%, 95%), introducing the idea of mutual
exclusivity. Coverage at 95% must replace coverage at
80%. Each of the combinations of interventions is
analysed taking into account all possible interactions
in costs or effectiveness. Combinations of interventions
must be plausible. For example, emergency obstetric
care interventions are not included unless skilled birth
attendance is implemented at the same time. The
number of possible combinations increases rapidly
with the addition of each new intervention.
Education and debate
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programmes. Effectiveness was obtained by adjusting
efficacy by a factor between 0 and 1 to allow for less
than perfect adherence to recommended practices.
The adjustment factor was taken from the literature
whenever possible, with expert opinion the last resort.
Finally, the eligible population was multiplied by
coverage to determine the total numbers benefiting
from estimated effectiveness. No information was
available on the effect of increasing coverage on health
effects. We assumed, therefore, that the health benefit
of each child treated for pneumonia (unit effective-
ness), for example, did not vary with coverage.
It was rarely possible to obtain information on the
joint effectiveness of multiple interventions imple-
mented simultaneously. We therefore assumed that the
health effect was additive for interventions that affect
different health outcomes. For interventions acting on
the same outcome the joint effect was estimated by
multiplying the individual relative risks (box C on
bmj.com).
Population health effects
We used a population model, PopMod, to project the
effect of interventions on the aggregate healthy years
of life lived by a population, combining incidence,
prevalence, and mortality and estimates of disease
severity with information on intervention coverage
and effectiveness.25 The exception was for HIV and
AIDS, for which we used a model that allows death
rates to increase with time spent ill. Regional epidemi-
ology was taken from the latest internal WHO update
of the global burden of disease study.26
PopMod projects regional population over time,
allowing people to move in and out of disease states, or
die, in accordance with incidence and remission rates.
To derive a single indicator of population health, time
spent in each state is given a weight (health state valua-
tion or disability weight) reflecting disease severity.
Weights were taken from Murray and Lopez.27 The
population is projected for the length of time
necessary for people affected by the intervention to
live their full life course. The difference between the
aggregate number of healthy years lived by the
projected population in the intervention and in the “do
nothing” scenario is the population health gain attrib-
utable to the intervention.
The outcome indicator is essentially the number of
healthy years of life gained by an intervention, also
called the number of disability adjusted life years
(DALYs) averted. The mechanics of estimating DALYs
are virtually identical to those required to estimate
quality adjusted life years (QALYs), although there are
some differences in the interpretation (box D on bmj-
.com). The base case analysis discounts DALYs averted
in the future at 3% and gives greater weight to DALYs
averted during adulthood. This is relaxed in the sensi-
tivity analysis.
Calculating cost effectiveness
Cost effectiveness analysis generally considers the costs
and effects of adding new interventions to current
practice or of replacing an existing intervention with
another targeting the same condition. Here we
evaluate the full set of existing interventions by first
considering what would happen to population health
if they all ceased to be implemented today. This is the
null or do nothing scenario (box E on bmj.com). The
current population is followed over time in PopMod
assuming that all interventions cease, using the
information on epidemiology, effectiveness, and the
current coverage of interventions described earlier.
Next, we trace the implications for population
health of adding all possible interventions singly and in
various combinations, against the baseline of doing
nothing. The difference is the gain in health due to the
reduction in disease burden from the intervention(s)
(DALYs averted). The costs of each scenario are then
compared with the gain to identify the most cost effec-
tive set of interventions at different levels of resource
availability. The comparison of the current mix against
the optimal set for the resources currently available
shows areas of inefficiency. The optimal set for higher
resource levels shows what should be done if existing
efforts to raise more resources are successful.
Interpreting results
For each paper in this series, the cost of every
intervention and package is plotted against the corre-
sponding population health effect relative to the do
nothing scenario for that condition. We then
determine the order in which interventions would be
chosen and combined at given levels of resource avail-
ability if cost effectiveness were the only consideration.
The graphical depiction we call the expansion path. To
understand this process, two cost effectiveness ratios
are defined. The incremental cost effectiveness ratio
denotes the additional costs and benefits of a new
intervention or package relative to what existed
before, the previous point on the expansion path.
Comparison of the incremental cost effectiveness
ratio to doing nothing is sometimes called the average
cost effectiveness ratio. Box F on bmj.com provides an
example of how the expansion path is determined and
interpreted.
Uncertainty
Cost effectiveness is an inexact science, particularly
when data are limited and of poor quality. Many
sources of uncertainty cannot be captured by statistical
confidence intervals because no sampling is involved.
Probabilistic uncertainty analysis has been developed
for these circumstances, but technical limitations do
not yet allow it to include the complex correlations
Box 2: International dollars
International dollars are used to account for
differences in price levels across countries. The
exchange rate for domestic currency into international
dollars is the amount of domestic currency required to
purchase the same quantity of goods and services as
$1 could purchase in the US. For low income
countries, national income measured in terms of
international dollars is generally higher than it is in US
dollars because domestic costs for many goods are
lower than in the US. Table B on bmj.com gives
conversions from international to US dollars.
Education and debate
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inherent in combining the large set of interventions in
this series (box G on bmj.com).28 29
Accordingly, the individual papers incorporate
relatively simple forms of sensitivity analysis that are
easier to understand. In the final paper, the results of
all the disease specific analyses are integrated to
develop priorities from the perspective of a policy
maker responsible for all health millennium develop-
ment goals, not just one. For this cross disease analysis,
we believe it is not possible to recommend that an
intervention shown to cost $45 per DALY averted is
more efficient than one costing $60, given the nature
of the uncertainties. However, we are much more con-
fident that $45 per DALY is better than $450 per
DALY. For the broad comparison across goals we,
therefore, interpret cost effectiveness figures in broad
order of magnitude ranges (box H on bmj.com).
Conclusions
Progress in the five years since the Millennium Decla-
ration was signed has been disappointing.1 More funds
to improve health in poor countries are urgently
required, but money alone will not be sufficient to
achieve the goals. Open discussion of ways of getting
more from the available resources is required, both to
allow countries to improve the health of their popula-
tions more quickly and to give potential donors confi-
dence that new funds will be used effectively.
Application of the methods outlined in this paper, as
described in the next six articles in this series, will
facilitate open debate and encourage changes in strat-
egies where necessary.
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Summary points
To achieve the millennium development goals,
the resources currently available need to be used
effectively
In addition, resources need to be found to scale
up many interventions simultaneously
The methods used in this series allow for the
assessment of the costs and health effects of
current interventions and those that could be
used when new resources are available
They incorporate interactions in costs and effects
when interventions are undertaken concurrently,
and at varying levels of coverage
Standardised methods are used to enhance
comparability
The focus is on two regions where unmet health
needs are enormous, one in sub-Sarahan Africa
and one in South-East Asia
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